Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Jian Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7217-0111; OpenAlex author ID A5100409879. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Bibliometric analysis of global research trends in pancreatic cancer immunotherapy. Co-author DOI 10.1080/21645515.2025.2538330↗
  2. Co-alteration of Myc and RTK-RAS pathways defines a liver-metastatic propensity and immune-cold subgroup of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.gendis.2023.05.006↗
  3. Circ_0000284 upregulates RHPN2 to facilitate pancreatic cancer proliferation, metastasis, and angiogenesis through sponging miR-1179. Co-author DOI 10.1002/jbt.23274↗
  4. Awaken Immune Cells by Hapten Enhanced Intratumoral Chemotherapy with Penicillin Prolong Pancreatic Cancer Survival. Last author DOI 10.7150/jca.82985↗
  5. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. First author DOI 10.1002/1878-0261.12757↗
  6. MiRNA-Mediated Subpathway Identification and Network Module Analysis to Reveal Prognostic Markers in Human Pancreatic Cancer. Co-author DOI 10.3389/fgene.2020.606940↗
  7. MiR-216a-5p inhibits tumorigenesis in Pancreatic Cancer by targeting TPT1/mTORC1 and is mediated by LINC01133. Co-author DOI 10.7150/ijbs.46822↗
  8. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. Co-author PMID 30788003↗
  9. Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma. Last author DOI 10.1186/1477-7819-12-49↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tong Fu · 1 shared paper, 2025 · strength 0.27
  2. Yongping Zhou · 1 shared paper, 2025 · strength 0.27
  3. Xu Zhang · 1 shared paper, 2025 · strength 0.27
  4. Li Ren · 1 shared paper, 2023 · strength 0.26
  5. Yuyuan Zhang · 1 shared paper, 2024 · strength 0.21
  6. Peng Luo · 1 shared paper, 2024 · strength 0.21
  7. Xinwei Han · 1 shared paper, 2024 · strength 0.21
  8. Baofa Yu · 1 shared paper, 2023 · strength 0.18
  9. Tingbo Liang · 2 shared papers, 2019–2020 · strength 0.18
  10. Wei Feng · 1 shared paper, 2020 · strength 0.10
  11. Hongmei Wang · 1 shared paper, 2020 · strength 0.10
  12. Bingfeng Huang · 1 shared paper, 2019 · strength 0.09
  13. Jianxin Wang · 1 shared paper, 2019 · strength 0.09
  14. Xiao Zhi · 1 shared paper, 2020 · strength 0.09
  15. Tao Wei · 1 shared paper, 2020 · strength 0.09
  16. Qi Chen · 1 shared paper, 2020 · strength 0.09
  17. Xiang Li · 1 shared paper, 2020 · strength 0.09
  18. Qi Zhang · 1 shared paper, 2020 · strength 0.09
  19. Tao Ma · 1 shared paper, 2020 · strength 0.09
  20. Wei Chen · 1 shared paper, 2020 · strength 0.09
  21. Risheng Que · 1 shared paper, 2020 · strength 0.09
  22. Jiaqi Yang · 1 shared paper, 2020 · strength 0.09
  23. Jin Li · 1 shared paper, 2020 · strength 0.09
  24. Xueli Bai · 1 shared paper, 2020 · strength 0.09
  25. Yuejuan Liu · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.